New #JAKi #disease #results #Baricitinib in #alopecia #areata esp 4mg/d #Upadacitinib in Crohn’s #Upa in #polyarticular #JIA & kid #PsA +RCT of UPA in #GCA Awaiting results of #SLE With #deucravicitinib & UPA #RCTs #EULAR2024 @eular_org @RheumNow

I think if we’re worried about JAK inhibitor safety, we need to be doing it right. I wrote this for @RheumNow for #EULAR2024 ahead of my debate against @Janetbirdope, but also drew my inspiration from @RADoctor in @ACR_Journals - a must read: https://t.co/RA6ktQAzqO https://t.co/lltDbtxpAg

• The Art of Communicating Risk and Benefit to Promote Shared Decision‐Making, In…
• https://twitter.com/rheumnow/status/1801615707999756628

#EULAR2024 Please find my short blog on the Impact of Safety Warning Update on the use of JAK-inhibitors @RheumNow https://t.co/Z4pujQRQ9h https://t.co/QRUnJInblH

• Impact of regulatory warning on JAK inhibitors | RheumNow
• https://twitter.com/Yuz6Yusof/status/1801655701107790163/photo/1

#EULAR2024 POS0390 What impact of regulatory warning on JAK-i on access to therapy? Data from UK BSSR-BR reported 4 in 5 #RA patients would have been considered ‘high-risk’. Of these, 28% had failed ≥3 biologics; so no suitable alternatives. Enormously impacted @RheumNow https://t.co/XeS9qHXSpH

• https://twitter.com/Yuz6Yusof/status/1801634766610964984/photo/1

#opportunistic inf in #autoimmune dz 🎤 @khyrich 👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸) 👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6 👉 🙅‍♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️ 🔗#eular 2022 guide: https://t.co/PIpGpTrH28 #eular2024 #rheumx @RheumNow https://t.co/kouXvradiC

• https://ard.bmj.com/content/annrheumdis/82/6/742.full.pdf
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1
• https://twitter.com/AMinalyan/status/1801606024576565284/photo/1

The art of talking about risks with our patients https://t.co/V0JQ1EsbKc https://t.co/GSTbPu0EXZ

• The art of talking about risks with our patients | RheumNow

Having said that, the EMA warning has elements making it extremely tough: - still very broad criteria that capture 80% of people who were starting JAKi - the need for "no suitable treatment alternatives" before using a JAKi, right across all diseases (not just RA) 3/ #EULAR2024 https://t.co/IsrYO7qzqM

• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1
• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1
• https://twitter.com/drdavidliew/status/1801144544035225737/photo/1